Summary of research groups

The Advanced Imaging Group is a collaboration of researchers who focus on brain imaging work related to Alzheimer’s disease and related dementias. Co-leads: Prof Barnes and Prof Cash.

Most studies at the DRC involve biomarkers at some level; however, we have a number of studies which are dedicated to investigating biomarkers of dementia-related diseases across the clinical spectrum

The Brain Behaviour Group aims to identify cognitive & physiological changes, particularly complex sound processing, that link damaging proteins in the brain to specific symptoms. PI: Prof Warren

Clinical trials are vitally important to allow us to develop and test medicines that may slow the progression of diseases causing dementia, or even prevent the onset of symptoms. PI: Prof Mummery

We see people with familial Alzheimer's disease as part of several different studies that aim to improve our understanding of the disease, early detection and monitoring of changes. PI: Prof Fox.

GENFI is an international multicentre study in Europe and Canada investigating genetic forms of FTD. PI: Prof Rohrer.

Insight46 aims to identify brain changes that accompany healthy ageing and to detect early changes that might help predict who is at risk of developing dementia. PI: Prof Schott.

The Minimal Interval Resonance Imaging in Alzheimer's Disease (MIRIAD) dataset is a series of longitudinal volumetric T1 MRI scans of 46 mild-moderate Alzheimer's subjects and 23 controls.

We aim to shed light on how Parkinson’s disease can affect thinking and memory, with an ultimate goal to develop treatments to slow the progression of dementia in Parkinson’s Disease. PI: Prof Weil

The PCA group runs studies aimed at understanding the causes of posterior cortical atrophy and improve diagnosis and support for people living with posterior cortical atrophy. PI: Dr Keir Yong.

​​This programme will be the largest study of psychological wellbeing in people with rarer dementias and their carers, with ~10,300 participants. PI: Prof Stott; Co-PI: Dr Brotherhood.

The aim of our group is to use the SILK method to a) interrogate disease mechanisms and b) measure treatment responses across a range of neurodegenerative diseases. PI: Dr Paterson.